Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,018 across all filing types
Latest filing 2020-06-19 Transaction in Own Shar…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
200619 - Verwerving en vervreemding van eigen aandelen.pdf
Transaction in Own Shares Classification · 1% confidence The document text is titled "Verwerving en vervreemding van eigen aandelen" (Acquisition and disposal of own shares) and details transactions where UCB NV bought back its own shares ('Verwerving van eigen aandelen') and disposed of shares through employee incentive plans ('Vervreemding van eigen aandelen') between June 11, 2020, and June 16, 2020. This activity specifically relates to the company buying back or issuing its own shares, which directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS.
2020-06-19 Dutch
2020611 - UCB Acquisitions and disposals of own shares.pdf
Transaction in Own Shares Classification · 1% confidence The document is titled "Acquisitions and disposals of own shares" and details the repurchase (acquisition) and disposal of UCB SA/NV's own shares under a Share Repurchase Program. This activity directly relates to the company's treasury stock transactions or share buybacks. Reviewing the filing definitions, the category "Transaction in Own Shares (Code: POS)" is defined as "Report of the company buying back or selling its own shares (share repurchase/issuance)". The content perfectly matches this definition, detailing the number of shares repurchased and disposed of between specific dates in June 2020.
2020-06-11 English
2020611 - Rachat et Aliénation d'actions propres.pdf
Transaction in Own Shares Classification · 1% confidence The document is titled "Rachat et Aliénation d'actions propres" (Repurchase and Disposal of Own Shares) and details transactions where UCB SA bought back its own shares (Rachat d'actions propres) and disposed of shares (Aliénation d'actions propres) related to employee stock options. This activity directly corresponds to the definition of a company buying back or selling its own shares, which is classified as 'Transaction in Own Shares'. The corresponding code is POS. The document is a regulatory announcement dated June 11, 2020, providing specific transaction details, not a general report announcement (RPA) or a broad regulatory filing (RNS).
2020-06-11 French
20200611 - Verwerving en vervreemding van eigen aandelen.pdf
Transaction in Own Shares Classification · 1% confidence The document is titled "Verwerving en vervreemding van eigen aandelen" (Acquisition and disposal of own shares) and details specific transactions (buybacks and disposals) of UCB shares between June 2 and June 11, 2020. This activity directly relates to the company managing its own stock, which falls under the category of 'Transaction in Own Shares'. The code for this is POS. The document is a formal announcement ('gereglementeerde informatie') detailing the transactions, not just an announcement that a report is forthcoming.
2020-06-11 Dutch
UCB Engage press release June 05 2020
M&A Activity Classification · 1% confidence The document is a press release dated June 5, 2020, announcing UCB's acquisition of Engage Therapeutics. It details the terms of the deal (upfront payment, milestones) and the strategic rationale related to the drug *Staccato®* Alprazolam. The text explicitly states it is 'regulated information – inside information' and contains forward-looking statements typical of corporate news releases regarding M&A activity. This content strongly aligns with an announcement regarding a major corporate transaction, specifically a takeover or acquisition proposal, which corresponds to the 'M&A Activity' category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement (DEF 14A).
2020-06-05 English
UCB Engage press release June 05 2020 FR
M&A Activity Classification · 1% confidence The document text is a press release dated June 5, 2020, announcing that UCB has acquired Engage Therapeutics. The content details the terms of the acquisition (payment structure, rights transfer) and the strategic rationale related to the drug *Staccato®* Alprazolam. This type of announcement, concerning corporate transactions like mergers or acquisitions, directly corresponds to the M&A Activity category. The document is a formal announcement, not a regulatory filing like a 10-K or a general regulatory notice (RNS), but specifically addresses a takeover/acquisition proposal. Therefore, the appropriate code is TAR (M&A Activity). The document length (12,793 chars) confirms it is the primary announcement, not just a brief notification of publication (RPA).
2020-06-05 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.